The FDA approved a generic fidaxomicin from Sandoz on 13 August under ANDA 220465. Alongside it, a supplemental approval for a vancomycin hydrochloride product from Hikma was issued on 18 August. These are the only new regulatory items the infectious diseases sweep returned.
Generic approval of fidaxomicin is more consequential than the routine tone of an ANDA notice suggests. Fidaxomicin outperforms vancomycin on recurrence in Clostridioides difficile infection, and guidelines have preferred it for years, but price has kept it off most formularies outside well-funded systems. Generic entry is the mechanism by which a guideline-preferred drug becomes an actually-used drug, and this is the first step in that process.
The qualification is geographic. A US generic approval does not put the drug on an Indian shelf, and it does not change Indian pricing directly. What it does is establish a manufacturing route and start the erosion of the originator price, which historically precedes wider availability by a few years.
What the sweep does not cover is worth saying plainly. It watches FDA drug approvals and enforcement actions. It does not see CDSCO notices, WHO guidance, IDSA or ESCMID statements published as web pages, or antimicrobial resistance surveillance reports from ICMR. On any given day, the most consequential infectious diseases guidance may be in one of those and will not appear here.
- Note fidaxomicin generic entry as the beginning of a price change, not an immediate availability change outside the US
- Where fidaxomicin is accessible, it remains preferred over vancomycin for reducing recurrence in C. difficile infection
- Continue to treat C. difficile recurrence risk as the main driver of agent choice, alongside cost
- Remember the sweep's blind spots: CDSCO, WHO, IDSA, ESCMID and ICMR guidance do not reach this feed
- Review local antibiotic policy against current national resistance data rather than against these approval notices
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free